Supplementary Online Content

Colboc H, Moguelet P, Bazin D, et al; for the Groupe Angio-Dermatologie of the French Society of Dermatology. Localization, morphologic features, and chemical composition of calciphylaxis-related skin deposits in patients with calcific uremic arteriologathy. <i>JAMA Dermatol</i> . Published online May 22, 2019. doi:10.1001/jamadermatol.2019.0381
eTable. Univariate and Multivariate Analyses for the Risk of Death Related to CUA
This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Univariate and Multivariate Analyses for the Risk of Death Related to CUA

Calcific uremic arteriolopathy			P value	
Nonsurvivors	Survivors	OR (95% CI)	Univariate	Multivariate
28.6% vs 85.7%	71.4% vs 14.3%	15 (1.47–152.5)	.0228	.019
61.5 [33–88]	65 [49–89]	-	.36	-
50% vs 38.9%	50% vs 61.1%	1.57 (0.33–7.48)	.57	-
43.4% vs 40%	56.6% vs 60%	1.15 (0.16–8.2)	1	-
42.3% vs 50%	57.7% vs 50%	0.73 (0.04–13)	1	-
42.1% vs 44.4%	57.9% vs 55.6%	0.91 (0.18–4.5)	1	-
28.6% vs 57.1%	71.4% vs 42.9%	0.3 (0.06–1.44)	.25	-
30% vs 50%	70% vs 50%	0.43 (0.08–2.2)	.43	-
42.9% vs 42.9%	57.1% vs 57.1%	1 (0.22–4.47)	1	-
	Nonsurvivors 28.6% vs 85.7% 61.5 [33–88] 50% vs 38.9% 43.4% vs 40% 42.3% vs 50% 42.1% vs 44.4% 28.6% vs 57.1% 30% vs 50%	Nonsurvivors Survivors 28.6% vs 85.7% 71.4% vs 14.3% 61.5 [33–88] 65 [49–89] 50% vs 38.9% 50% vs 61.1% 43.4% vs 40% 56.6% vs 60% 42.3% vs 50% 57.7% vs 50% 42.1% vs 44.4% 57.9% vs 55.6% 28.6% vs 57.1% 71.4% vs 42.9% 30% vs 50% 70% vs 50%	Nonsurvivors Survivors OR (95% CI) 28.6% vs 85.7% 71.4% vs 14.3% 15 (1.47–152.5) 61.5 [33–88] 65 [49–89] - 50% vs 38.9% 50% vs 61.1% 1.57 (0.33–7.48) 43.4% vs 40% 56.6% vs 60% 1.15 (0.16–8.2) 42.3% vs 50% 57.7% vs 50% 0.73 (0.04–13) 42.1% vs 44.4% 57.9% vs 55.6% 0.91 (0.18–4.5) 28.6% vs 57.1% 71.4% vs 42.9% 0.3 (0.06–1.44) 30% vs 50% 70% vs 50% 0.43 (0.08–2.2)	Nonsurvivors Survivors OR (95% CI) Univariate 28.6% vs 85.7% 71.4% vs 14.3% 15 (1.47–152.5) .0228 61.5 [33–88] 65 [49–89] - .36 50% vs 38.9% 50% vs 61.1% 1.57 (0.33–7.48) .57 43.4% vs 40% 56.6% vs 60% 1.15 (0.16–8.2) 1 42.3% vs 50% 57.7% vs 50% 0.73 (0.04–13) 1 42.1% vs 44.4% 57.9% vs 55.6% 0.91 (0.18–4.5) 1 28.6% vs 57.1% 71.4% vs 42.9% 0.3 (0.06–1.44) .25 30% vs 50% 70% vs 50% 0.43 (0.08–2.2) .43

Livedo reticularis (yes vs no)	46.2% vs 40%	53.8% vs 60%	1.29 (0.29–5.78)	.74	-
Ulceration (yes vs no)	45% vs 37.5%	55% vs 62.5%	1.36 (0.25–7.32)	1	_
Nodular lesions (yes vs no)	83.3% vs 31.8%	16.7% vs 68.2%	10.7 (1.04–109.78)	.053	.038
Indurated plaque (yes vs no)	40% vs 44.4%	60% vs 55.6%	0.83 (0.17–4)	1	-
Vascular thrombosis	30.4% vs 40%	69.6% vs 60%	1.04 (0.14–7.93)	1	-
Interstitial calcifications in biopsy (yes vs no)	33.3% vs 60%	66.7% vs 40%	0.33 (0.04–2.56)	.34	-
Serum calcium (mmol/L)	2.34 [2.14–2.65]	2.35 [1.98–2.84]		.86	
Serum phosphate (mmol/L)	1.8 [0.98–2.81]	1.51 [0.93–3.68]		.7	-
Calcium × phosphate product (mmol ² /L ²)	4.37 [2.22–6.83]	3.57 [1.87–8.65]		.7	-
Parathormone (pg/mL)	156 [19–1043]	261.5 [0.8–931]	-	.91	-
Albuminemia (g/L)	27 [18–43.6]	29.1 [21–36.2]	_	.75	_

Data are expressed as median [range], unless stated otherwise.

CUA, calcific uremic arteriolopathy; OR: odds ratio; CI: confidence interval.